Journal
BIOCONJUGATE CHEMISTRY
Volume 25, Issue 8, Pages 1402-1407Publisher
AMER CHEMICAL SOC
DOI: 10.1021/bc500276m
Keywords
-
Categories
Funding
- National Institutes of Health [DP1CA174426]
- Lymphoma Research Foundation
- Klorfine Foundation
Ask authors/readers for more resources
Current routes for synthesizing antibody-drug conjugates commonly rely on maleimide linkers to react with cysteine thiols. However, thioether exchange with metabolites and serum proteins can compromise conjugate stability and diminish in vivo efficacy. We report the application of a phenyloxadiazole sulfone linker for the preparation of trastuziunab conjugates. This sulfone linker site-specifically labeled engineered cysteine residues in THIOMABs and improved antibody conjugate stability in human plasma at sites previously shown to be labile for maleimide conjugates. Similarly, sulfone conjugation with selenocysteine in an anti-ROR1 scFv-Fc improved human plasma stability relative to maleimide conjugation. Kinetically controlled labeling of a THIOMAB containing two cysteine substitutions was also achieved, offering a strategy for producing antibody conjugates with expanded valency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available